Anti-invasive Activity of Ethanol Extracts of Ganoderma lucidum through Tightening of Tight Junctions and Inhibition of Matrix Metalloproteinase Activities in Human Gastric Carcinoma Cells

JAMS Journal of Acupuncture and Meridian Studies

Volumn 4, Issue 4, 2011, Pages 225-235

  Jang, Kyung Jun ^a   Son, In seok ^a   Shin, Dong Yeok ^a   Yoon, Hyun Min ^a   Choi, Yung Hyun ^a,b  

^a Dong Eui University   (South Korea)

^b Dong Eui University   (South Korea)

Author keywords

AGS; Ganoderma lucidum; Invasion; Tight junction

Indexed keywords

CLAUDIN; GANODERMA LUCIDUM EXTRACT; GELATINASE A; GELATINASE B; KRUPPEL LIKE FACTOR 6; MESSENGER RNA; TISSUE INHIBITOR OF METALLOPROTEINASE; UVOMORULIN;

ARTICLE; CARCINOMA CELL; CELL INVASION; CELL MOTILITY; CELL TRANSPORT; CONTROLLED STUDY; ELECTRIC RESISTANCE; ENZYME INHIBITION; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SNAIL; STOMACH CARCINOMA; TIGHT JUNCTION; UPREGULATION;

EID: 84155165538     PISSN: 20052901     EISSN: 20938152     Source Type: Journal    
DOI: 10.1016/j.jams.2011.09.013     Document Type: Article

References (53)

1. Hart I.R., Goode N.T., Wilson R.E. Molecular aspects of the metastatic cascade. Biochem Biophys Acta 1989, 989:65-84.
2. Jiang W.G., Puntis M.C.A., Hallet M.B. The molecular and cellular basis of cancer invasion and metastasis and its implications for treatment. Br J Surg 1994, 81:1576-1590.
3. Martin T.A., Jiang W.G. Loss of tight junction barrier function and its role in cancer metastasis. Biochim Biophys Acta 2009, 1788:872-891.
4. Duffy M.I., Maguire T.M., Hill A., McDermott E., O'Higgins N. Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res 2000, 2:252-257.
5. Vihinen P., Ala-aho R., Kähäri V.M. Matrix metalloproteinases as therapeutic targets in cancer. Curr Cancer Drug Targets 2005, 5:203-220.
6. Matrisian L.M. The matrix-degrading metalloproteinases. Bioessays 1992, 14:455-463.
7. Mook O.R., Frederiks W.M., Van Noorden C.J. The role of gelatinases in colorectal cancer progression and metastasis. Biochim Biophys Acta 2004, 1705:69-89.
8. Usami Y., Satake S., Nakayama F., Matsumoto M., Ohnuma K., Komori T., et al. Snail-associated epithelial-mesenchymal transition promotes oesophageal squamous cell carcinoma motility and progression. J Pathol 2008, 215:330-339.
9. Lambert E., Dasse E., Haye B., Petitfrere E. TIMPs as multifacial proteins. Crit Rev Oncol Hematol 2004, 49:187-198.
10. Soler A.P., Miller R.D., Laughlin K.V., Carp N.Z., Klurfeld D.M., Mullin J.M. Increased tight junctional permeability is associated with the development of colon cancer. Carcinogenesis 1999, 20:1425-1431.
11. Schneeberger E.E., Lynch R.D. The tight junction: a multifunctional complex. Am J Physiol Cell Physiol 2004, 286:C1213-C1228.
12. Morin P.J. Claudin proteins in human cancer: promising new targets for diagnosis and therapy. Cancer Res 2005, 65:9603-9606.
13. Kominsky S.L., Argani P., Korz D., Evron E., Raman V., Garrett E., et al. Loss of the tight junction protein Claudin-7 correlates with histological grade in both ductal carcinoma in situ and invasive ductal carcinoma of the breast. Oncogene 2003, 22:2021-2033.
14. Mahajna J., Dotan N., Zaidman B.Z., Petrova R.D., Wasser S.P. Pharmacological values of medicinal mushrooms for prostate cancer therapy: the case of Ganoderma lucidum. Nutr Cancer 2009, 61:6-26.
15. Boh B., Berovic M., Zhang J., Zhi-Bin L. Ganoderma lucidum and its pharmaceutically active compounds. Biotechnol Annu Rev 2007, 13:265-301.
16. Paterson R.R. Ganoderma - a therapeutic fungal biofactory. Phytochemistry 2006, 67:1985-2001.
17. Yuen J.W., Gohel M.D. Anticancer effects of Ganoderma lucidum: a review of scientific evidence. Nutr Cancer 2005, 53:11-17.
18. Chen J.G., Yang C.P., Cammer M., Horwitz S.B. Gene expression and mitotic exit induced by microtubule-stabilizing drugs. Cancer Res 2003, 63:7891-7899.
19. Chien C.M., Cheng J.L., Chang W.T., Tien M.H., Tsao C.M., Chang Y.H., et al. Polysaccharides of Ganoderma lucidum alter cell immunophenotypic expression and enhance CD56+NK-cell cytotoxicity in cord blood. Bioorg Med Chem 2004, 12:5603-5609.
20. Lin Z.B. Cellular and molecular mechanisms of immuno-modulation by Ganoderma lucidum. J Pharmacol Sci 2005, 99:144-153.
21. Hu H., Ahn N.S., Yang X., Lee Y.S., Kang K.S. Ganoderma lucidum extract induces cell cycle arrest and apoptosis in MCF-7 human breast cancer cell. Int J Cancer 2002, 102:250-253.
22. Sliva D., Labarrere C., Slivova V., Sedlak M., Lloyd F.P., Ho N.W. Ganoderma lucidum suppresses motility of highly invasive breast and prostate cancer cells. Biochem Biophys Res Commun 2002, 298:603-612.
23. Lin S.B., Li C.H., Lee S.S., Kan L.S. Triterpene-enriched extracts from Ganoderma lucidum inhibit growth of hepatoma cells via suppressing protein kinase C, activating mitogen-activated protein kinases and G2-phase cell cycle arrest. Life Sci 2003, 72:2381-2390.
24. Jiang J.H., Slivova V., Valachovicova T., Harvey K., Sliva D. Ganoderma lucidum inhibits proliferation and induces apoptosis in human prostate cancer cells PC-3. Int J Oncol 2004, 24:1093-1099.
25. Hong K.J., Dunn D.M., Shen C.L., Pence B.C. Effects of Ganoderma lucidum on apoptotic and anti-inflammatory function in HT-29 human colonic carcinoma cells. Phytother Res 2004, 18:768-770.
26. Stanley G., Harvey K., Slivova V., Jiang J., Sliva D. Ganoderma lucidum suppresses angiogenesis through the inhibition of secretion of VEGF and TGF-β1 from prostate cancer cells. Biochem Biophys Res Commun 2005, 330:46-52.
27. Müller C.I., Kumagai T., O'Kelly J., Seeram N.P., Heber D., Koeffler H.P. Ganoderma lucidum causes apoptosis in leukemia, lymphoma and multiple myeloma cells. Leuk Res 2006, 30:841-848.
28. Jang K.J., Han M.H., Lee B.H., Kim B.W., Kim C.H., Yoon H.M., et al. Induction of apoptosis by ethanol extracts of Ganoderma lucidum in human gastric carcinoma cells. J Acupunct Meridian Stud 2010, 3:24-31.
29. Kim S.O., Choi B.T., Choi I.W., Cheong J., Kim G.Y., Kwon T.K., et al. Anti-invasive activity of histone deacetylase inhibitors via the induction of Egr-1 and the modulation of tight junction-related proteins in human hepatocarcinoma cells. BMB Rep 2009, 42:655-660.
30. Lee Y.R., Noh E.M., Jeong E.Y., Yun S.K., Jeong Y.J., Kim J.H., et al. Cordycepin inhibits UVB-induced matrix metalloproteinase expression by suppressing the NF-κB pathway in human dermal fibroblasts. Exp Mol Med 2009, 41:548-554.
31. Kominsky S.L. Claudins: emerging targets for cancer therapy. Expert Rev Mol Med 2006, 8:1-11.
32. Nelson W.J., Nusse R. Convergence of Wnt, β-catenin, and cadherin pathways. Science 2004, 303:1483-1487.
33. McLachlan R.W., Yap A.S. Not so simple: the complexity of phosphotyrosine signaling at cadherin adhesive contacts. J Mol Med 2007, 85:545-554.
34. Yokoyama K., Kamata N., Hayashi E., Hoteiya T., Ueda N., Fujimoto R., et al. Reverse correlation of E-cadherin and snail expression in oral squamous cell carcinoma cells in vitro. Oral Oncol 2001, 37:65-71.
35. Uzui H., Harpf A., Liu M., Doherty T.M., Shukla A., Chai N. Increased expression of membrane type 3-matrix metalloproteinase in human atherosclerotic plaque: role of activated macrophages and inflammatory cytokines. Circulation 2002, 106:3024-3030.
36. Choi Y.H., Choi W.Y., Hong S.H., Kim S.O., Kim G.Y., Lee W.H., et al. Anti-invasive activity of sanguinarine through modulation of tight junctions and matrix metalloproteinase activities in MDA-MB-231 human breast carcinoma cells. Chem Biol Interact 2009, 179:185-191.
37. Moon D.O., Choi Y.H., Moon S.K., Kim W.J., Kim G.Y. Butein suppresses the expression of nuclear factor-kappa B-mediated matrix metalloproteinase-9 and vascular endothelial growth factor in prostate cancer cells. Toxicol In Vitro 2010, 24:1927-1934.
38. Shin D.Y., Kim G.Y., Kim J.I., Yoon M.K., Kwon T.K., Lee S.J., et al. Anti-invasive activity of diallyl disulfide through tightening of tight junctions and inhibition of matrix metalloproteinase activities in LNCaP prostate cancer cells. Toxicol In Vitro 2010, 24:1569-1576.
39. Shin D.Y., Ryu C.H., Lee W.S., Kim D.C., Kim S.H., Hah Y.S., et al. Induction of apoptosis and inhibition of invasion in human hepatoma cells by anthocyanins from meoru. Ann N Y Acad Sci 2009, 1171:137-148.
40. Latorre I.J., Roh M.H., Frese K.K., Weiss R.S., Margolis B., Javier R.T. Viral oncoprotein-induced mislocalization of select PDZ proteins disrupts tight junctions and causes polarity defects in epithelial cells. J Cell Sci 2005, 118:4283-4293.
41. Verghese G.M., Gutknecht M.F., Caughey G.H. Prostasin regulates epithelial monolayer function: cell-specific Gpld1-mediated secretion and functional role for GPI anchor. Am J Physiol Cell Physiol 2006, 291:C1258-C1270.
42. Kim S.O., Kwon J.I., Jeong Y.K., Kim G.Y., Kim N.D., Choi Y.H. Induction of Egr-1 is associated with anti-metastatic and anti-invasive ability of β-lapachone in human hepatocarcinoma cells. Biosci Biotechnol Biochem 2007, 71:2169-2176.
43. Mullin J.M., Agostino N., Rendon-Huerta E., Thornton J.J. Keynote review: epithelial and endothelial barriers in human disease. Drug Discov Today 2005, 10:395-408.
44. Kominsky S.L., Vali M., Korz D., Gabig T.G., Weitzman S.A., Argani P., et al. Clostridium perfringens enterotoxin elicits rapid and specific cytolysis of breast carcinoma cells mediated through tight junction proteins Claudin 3 and 4. Am J Pathol 2004, 164:1627-1633.
45. Tokés A.M., Kulka J., Paku S., Szik A., Páska C., Novák P.K., et al. Claudin-1, -3 and -4 proteins and mRNA expression in benign and malignant breast lesions: a research study. Breast Cancer Res 2005, 7:R296-R305.
46. Cunningham S.C., Kamangar F., Kim M.P., Hammoud S., Haque R., Iacobuzio-Donahue C.A., et al. Claudin-4, mitogen activated protein kinase kinase 4, and stratifin are markers of gastric adenocarcinoma precursor lesions. Cancer Epidemiol Biomarkers Prev 2004, 15:281-287.
47. Rangel L.B., Agarwal R., D'Souza T., Pizer E.S., Alò P.L., Lancaster W.D., et al. Tight junction proteins claudin-3 and claudin-4 are frequently overexpressed in ovarian cancer but not in ovarian cystadenomas. Clin Cancer Res 2003, 9:2567-2575.
48. Michl P., Barth C., Buchholz M., Lerch M.M., Rolke M., Holzmann K.H., et al. Claudin-4 expression decreases invasiveness and metastatic potential of pancreatic cancer. Cancer Res 2003, 63:6265-6271.
49. Agarwal R., D'Souza T., Morin P.J. Claudin-3 and claudin-4 expression in ovarian epithelial cells enhances invasion and is associated with increased matrix metalloproteinase-2 activity. Cancer Res 2005, 65:7378-7385.
50. Yoon C.H., Kim M.J., Park M.J., Park I.C., Hwang S.G., An S., et al. Claudin-1 acts through c-Abl-protein kinase Cdelta (PKCδ) signaling and has a causal role in the acquisition of invasive capacity in human liver cells. J Biol Chem 2010, 285:226-233.
51. Miyamori H., Takino T., Kobayashi Y., Tokai H., Itoh Y., Seiki M., et al. Claudin promotes activation of pro-matrix metalloproteinase-2 mediated by membrane-type matrix metalloproteinases. J Biol Chem 2001, 276:28204-28211.
52. Ip Y.C., Cheung S.T., Lee Y.T., Ho J.C., Fan S.T. Inhibition of hepatocellular carcinoma invasion by suppression of Claudin-10 in HLE cells. Mol Cancer Ther 2007, 6:858-2867.
53. Van Itallie C.M., Anderson J.M. Claudins and epithelial paracellular transport. Annu Rev Physiol 2006, 68:403-429.